Blood Cancer Journal

Blood Cancer Journal is a peer-reviewed, fully open access journal published by Springer Nature that covers hematologic malignancies and related disorders, launched in 2011, with a 2025 Journal Impact Factor of 13.8（Blood Cancer Journal）是由（Springer Nature）出版的同行评审全开放获取期刊，聚焦血液系统恶性肿瘤及相关疾病，2011 年创刊，2025 年影响因子为 13.8。

Scope

• It seeks to publish articles of the highest quality related to hematologic malignancies and related disorders该刊致力于发表与血液系统恶性肿瘤及相关疾病相关的最高质量论文。^[1]
• It considers original research, reviews, guidelines and letters that are considered to be of high impact in the field接收原创研究、综述、指南以及在该领域具有高影响力的快报。
• Topics of particular interest include preclinical studies of new compounds, especially those that provide mechanistic insights关注主题包括新化合物的临床前研究，尤其是能提供机制洞见的工作。
• It publishes clinical trials and observations and reviews related to new drugs and current management of hematologic malignancies发表临床试验与观察性研究，以及有关新药与血液肿瘤现行管理的综述。^[2]
• It covers novel observations related to new mutations, molecular pathways and tumor genomics涵盖有关新突变、分子通路与肿瘤基因组学的新发现。
• It offers a forum for expedited publication of novel observations regarding new mutations or altered pathways and publishes a Current Treatment Algorithms article series为关于新突变或通路改变的新发现提供快速发表平台，并刊载（Current Treatment Algorithms）系列文章。
• Published work is freely discoverable and shareable, and the journal is a member of the Committee on Publication Ethics发表成果可自由发现与共享，该刊亦是（Committee on Publication Ethics）成员。

History

• The journal was launched in 2011 by Nature Publishing Group, now part of Springer Nature该刊于 2011 年由（Nature Publishing Group）创刊，现属（Springer Nature）。
• It is published online only under the single electronic ISSN 2044-5385该刊仅在线出版，使用单一电子刊号 2044-5385。
• It has been fully open access since launch自创刊起即采用全开放获取模式。
• Vincent Rajkumar has served as Editor-in-Chief since 2014（Vincent Rajkumar）自 2014 年起担任主编。
• The Current Treatment Algorithms series was launched in January 2018（Current Treatment Algorithms）系列于 2018 年 1 月推出。
• It is indexed in PubMed/MEDLINE, Scopus, Web of Science, DOAJ and BIOSIS Previews该刊被（PubMed/MEDLINE）、（Scopus）、（Web of Science）、（DOAJ）与（BIOSIS Previews）收录。
• Its Journal Impact Factor moved from 11.037 in 2021 to 9.812 in 2022, 11.6 in 2024 and 13.8 in 2025, ranking in the first quartile of hematology and oncology其影响因子由 2021 年的 11.037 变为 2022 年的 9.812、2024 年的 11.6 与 2025 年的 13.8，在血液学与肿瘤学类别均列第一四分位。

Editors

• The Editors-in-Chief are Vincent Rajkumar and Ayalew Tefferi, both professors at the Mayo Clinic in Rochester, Minnesota, United States主编为（Vincent Rajkumar）与（Ayalew Tefferi），二人均为美国明尼苏达州罗切斯特（Mayo Clinic）的教授。
• Rajkumar is Professor of Medicine and chairs the Mayo Clinic Myeloma, Amyloidosis and Dysproteinemia Group and the ECOG Myeloma Committee（Rajkumar）为医学教授，并担任（Mayo Clinic）骨髓瘤、淀粉样变与异常蛋白血症组以及（ECOG）骨髓瘤委员会主席。
• Tefferi is a hematologist whose clinical and laboratory interests focus on myeloid disorders including myelofibrosis, polycythemia vera, chronic myeloid leukemia and acute leukemia（Tefferi）为血液学家，临床与实验室兴趣集中于骨髓增殖性肿瘤等髓系疾病，包括骨髓纤维化、真性红细胞增多症、慢性髓性白血病与急性白血病。
• Rajkumar has published more than 230 peer-reviewed papers and also serves as a section editor for Leukemia（Rajkumar）已发表 230 余篇同行评审论文，并兼任（Leukemia）的栏目编辑。
• Tefferi has more than 1000 publications and serves on the editorial boards of several hematology journals（Tefferi）发表论著逾 1000 篇，并在多本血液学期刊担任编委。
• The journal states that world-leading voices form the expert editorial team, which offers rapid turnaround times with a median of 6 days to first editorial decision该刊称其编辑团队由领域内顶尖专家组成，审稿周转迅速，首次编辑决定的中位时间为 6 天。